Fmoc-L-methionine, molecular formula C₂₀H₂₁NO₄S and molecular weight 371.45 g·mol⁻¹, is released as a cGMP starting material with controls aligned to ICH Q7 for phase-appropriate therapeutic peptide manufacture. In a glass-lined, nitrogen-purged solid-phase peptide synthesis reactor with variable-speed agitation, the protected amino acid is introduced into methionine-bearing APIs such as teriparatide-class PTH_1–34 intermediates. Batch release records typically specify HPLC purity ≥ 99.0%, D-isomer ≤ 0.5%, residual TFA ≤ 0.1%, water by Karl Fischer ≤ 0.5%, and residual solvents within USP 467 limits. Compliance anchors include FDA 21 CFR 210/211, ICH Q7, ICH Q11 for starting material justification, ICH Q3C, and ICH Q3D with USP 232/233 elemental impurity verification. Release documentation supports Type II drug master file submissions and CEP applications for the peptide API.

Addition of Fmoc-L-methionine is performed at 3.0–4.0 equivalents relative to free resin-bound amino groups, as a 0.2–0.3 M solution in DMF, preactivated for 2–5 min with HBTU/HOBt/DIEA or HATU/DIEA. On Rink amide AM resin with substitution 0.4–0.6 mmol·g⁻¹, single couplings run for 45–90 min at 20–25 °C; double coupling is imposed when methionine occupies the N-terminal position adjacent to a hindered β-branched residue such as Val or Ile. Fmoc removal uses 20% piperidine in DMF in two stages of 5 min and 10 min, with reactor jacket temperature maintained at 22 ± 2 °C. The final cleavage solution is TFA/TIS/H₂O at 95:2.5:2.5 v/v/v for 2.5–3.5 h, and the crude peptide is precipitated in cold methyl tert-butyl ether at −20 °C. Purification uses preparative reverse-phase C18 or C8 columns with trifluoroacetic acid/acetonitrile mobile phases, followed by salt exchange to acetate and lyophilization. Typical preparative HPLC configurations use stainless steel C18 columns packed with 10 µm particles, 100 Å pore diameter, mobile phase flow rate 0.3–0.5 L·min⁻¹, and detection at 220 nm. Terminal finished-product forms of methionine-containing peptide APIs include sterile lyophilized drug substance, spray-dried API powder, and cartridge-filled solution after final formulation; methionine sulfoxide and sulfone content is controlled at release because oxidation during extended aeration produces charge variants that do not meet specification.

What process boundaries apply to methionine thioether oxidation in microwave-assisted CRO peptide assembly?

In automated microwave peptide synthesizers with fiber-optic temperature feedback, Fmoc-L-methionine is used at 2.0–3.0 equivalents relative to resin substitution for discovery-scale peptides, as a 0.1–0.15 M DMF solution, activated with DIC/Oxyma Pure at 1:1:1 molar ratio to the protected amino acid. Coupling at 70–75 °C for 2–4 min suppresses chain aggregation around the methionine residue, but the thioether side chain is not inert; repeated microwave exposure after methionine insertion raises methionine sulfoxide trace variants in the crude. Standard control is to limit the number of subsequent high-temperature coupling steps to ≤ 6 after Fmoc-Met incorporation, or to use room-temperature coupling for the following residue when the sequence permits. Deprotection still uses 20% piperidine in DMF at 75 °C for 30–60 s; Kaiser and chloranil tests are run after each cycle. Operating experience on 0.1 mmol instruments shows that delivery-line precipitation in DMF solvent with moisture above 0.01% shifts delivered molar equivalents below the prescribed 2.5 target and produces deletion variants at the methionine position.

Compliance for this CRO segment rests on ISO 9001:2015, ICH Q7 early-phase boundaries for nonclinical and preclinical batches, ICH Q3C residual solvent limits, and LC-MS identity confirmation against exact mass. Crude products are cleaved with TFA/TIS/H₂O/DODT at 92.5:2.5:2.5:2.5 v/v/v/v for 2 h, and methionine-containing peptides are precipitated in cold diethyl ether. RP-HPLC purity targets are usually ≥ 95% for research-grade peptides, with mass confirmation by electrospray ionization. Terminal product classes include methionine-bearing linear peptides for epitope mapping, biotinylated peptides, N-terminal fluorophore conjugates, disulfide-cyclized peptides, and peptide libraries with C-terminal Met handles. Methionine sulfoxide content in final research peptides is typically controlled below 1.0% by reducing the aeration interval after cleavage and by adding 0.1% methionine scavenger to the precipitation solvent when mass spectrometry indicates oxidative degradation.

Production of acetyl hexapeptide-8, acetyl-Glu-Glu-Met-Gln-Arg-Arg-NH₂, uses Fmoc-L-methionine as the internal Met residue within a cosmetic anti-wrinkle peptide synthesized on Rink amide AM resin. The synthesis begins with Fmoc-Arg(Pbf)-OH loading, then Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-L-methionine, Fmoc-Glu(OtBu)-OH, and Fmoc-Glu(OtBu)-OH; after final Fmoc removal, the N-terminus is capped with acetic anhydride/pyridine at 1:1 v/v. Addition ratio of Fmoc-L-methionine is 2.5–3.5 equivalents, as a 0.2 M solution in DMF, preactivated with HBTU/HOBt/DIEA at 4 °C for 5 min, then coupled at 20–25 °C for 60 min. Unreacted amino groups are capped after each coupling with acetic anhydride/DIEA/DMF at 5:6:89 v/v/v for 15 min to reduce deletion variants. Final cleavage uses TFA/TIS/H₂O at 95:2.5:2.5 v/v/v for 2.5 h; the crude peptide is precipitated in cold MTBE and converted from trifluoroacetate salt to acetate salt by anion exchange or repeated lyophilization from 0.1 M acetic acid.

Compliance for this downstream segment is anchored to ISO 22716 cosmetic GMP, EFfCI GMP, EU Regulation 1223/2009 Annex II safety exclusion screening, and INCI nomenclature. Final cosmetic peptide raw material is released by HPLC purity ≥ 95%, acetate content 10–20%, water ≤ 5%, residual TFA ≤ 0.1%, and solubility in water at 20 °C. The terminal product forms include lyophilized powder, preserved aqueous stock solutions at 0.5–1.0 mg·mL⁻¹ with phenoxyethanol, and serum formulation intermediates at final peptide concentrations of 0.01–0.05% w/w. Production-scale lyophilizers require controlled nucleation during freezing because amorphous peptide collapse in the batch freeze-drying step depresses reconstitution yield in cosmetic filling lines; methionine oxidation in the solid lyophilized cake is retarded by vacuum stoppering with residual moisture below 1.0%.

When Fmoc-L-methionine enters a 50-mer synthetic long-peptide vaccine run

A synthetic long-peptide immunogen with multiple internal methionine residues is assembled at 0.1–0.25 mmol scale on 2-chlorotrityl chloride or ChemMatrix resin using Fmoc-L-methionine at 3.5–4.5 equivalents per coupling. The higher molar excess compensates for steric congestion in sequences above 50 amino acids; activation uses HATU/DIEA in DMF at 0.15 M, with double coupling cycles of 20 min each and resin agitation under nitrogen overlay. This process is performed in a jacketed solid-phase reactor with filtered nitrogen sparging because methionine thioether oxidation accelerates when reactor headspace oxygen is not purged. Fmoc removal at each cycle uses 20% piperidine in DMF for 7–12 min, and the methionine-loaded resin is sampled after coupling for Kaiser test negativity and acetylation capping of remaining free amines. Peptide chain extension is delayed by 15–30 min after methionine incorporation when the following residue is a bulky Fmoc-amino acid such as Fmoc-Asn(Trt)-OH or Fmoc-Arg(Pbf)-OH, reducing incomplete coupling at the Met N-terminus.

Cleavage from the long-peptide support uses TFA/phenol/water/TIS at 88:5:5:2 v/v/v/v with ammonium iodide as a mild reductant, for 3–4 h at 25 °C. The thioether group of methionine is vulnerable to irreversible oxidation to methionine sulfoxide in the acidolytic cleavage step; scavenger selection is therefore not interchangeable with standard TFA/TIS/H₂O cocktails used for shorter peptides. Purification by preparative RP-HPLC to a single peak area ≥ 95% is followed by salt exchange and lyophilization. Compliance is governed by WHO guidelines for synthetic peptide vaccine characterization, ICH Q6B, USP 85 bacterial endotoxin testing with acceptance ≤ 0.5 EU·mg⁻¹, ICH Q3C, and ICH Q3D. Terminal product configurations include sterile-filtered synthetic long peptides, ovalbumin or KLH conjugates, and freeze-dried vaccine immunogen vials. Published process data specific to 50-mer methionine-containing sequences is limited; purification recovery often falls below 50% when oxidation is not controlled by scavenger ratios, and the methionine sulfoxide variant may co-elute closely with the target peak on C18 columns.

Diagnostic peptide substrate synthesis and the methionine scissile-bond stability problem

Fluorogenic and chromogenic peptide substrates used in enzyme activity assays are assembled with Fmoc-L-methionine when the recognized scissile sequence contains a Met residue at P₁ or P₂. The coupling stoichiometry is 3.0 equivalents relative to resin loading, as a 0.1 M solution in DMF, using HOBt/DIC activation at 0–4 °C for 20 min to minimize racemization. After resin loading, the peptide chain is elongated manually or in a semiautomated synthesizer, and the N-terminal fluorophore, usually AMC or FITC, is conjugated after final Fmoc removal. Cleavage uses TFA/TIS/H₂O at 95:2.5:2.5 v/v/v for 1.5–2 h; methionine sulfoxide formation during substrate cleavage is monitored by RP-HPLC at 215 nm and must remain ≤ 1.0% of the main peak because oxidized substrate is cleaved at a different rate by the target enzyme. Buffered aqueous dissolution of the peptide substrate is performed immediately before assay plate dispensing to limit dissolved-oxygen contact time.

The regulatory anchor for research-use diagnostic peptide components is ISO 9001:2015; when supplied as critical raw material for in vitro diagnostic kits, ISO 13485:2016 design control documentation is attached. Release data include HPLC purity ≥ 95%, identity by LC-MS, residual DMF ≤ 300 ppm, and TFA content ≤ 0.5%. Terminal product formats are 1–10 mg lyophilized substrate aliquots, organic stock solutions in DMSO at 10 mM, and pre-dispensed 96-well assay plates. Methionine oxidation in aqueous assay buffers at pH 7.4 over 24 h requires stabilizers such as 0.1 mM EDTA and 0.01% Tween 20 to reduce metal-catalyzed thioether oxidation in the final diagnostic kit.

Preloading of Fmoc-L-methionine onto 2-chlorotrityl chloride or Wang resin produces Fmoc-Met-resin building blocks that are subsequently used in fragment condensation and difficult sequence assembly. The loading reaction is conducted in anhydrous DCM with 1.2–1.5 equivalents of Fmoc-L-methionine relative to trityl chloride groups, in the presence of 4–6 equivalents of DIEA at 20–25 °C for 60–90 min. Unreacted trityl sites are capped with methanol/DIEA; the resulting substitution is controlled at 0.3–0.8 mmol·g⁻¹ by varying the initial resin-to-amino acid ratio. Compliance for this intermediate is linked to ICH Q7 when the preloaded resin is intended for cGMP peptide API manufacture, with release by HPLC assay of cleaved Fmoc-Met-OH and residual chloride ≤ 0.5%. Downstream, the preloaded resin shortens large-scale peptide synthesis cycles and reduces racemization associated with repetitive amino acid activation at the methionine C-terminal position. Terminal forms include bottle-inert packaged resin, single-use reactor cartridges, and custom-loaded resins for automated microwave peptide synthesizers. Because loaded resin is moisture-sensitive, storage requires −20 ± 5 °C under argon with desiccant and a retest interval of 12 months.